NCT01327781View on ClinicalTrials.gov

Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

March 25, 2011

Primary Completion Date

March 5, 2017

Study Completion Date

October 30, 2025

Conditions
HER2/Neu PositiveRecurrent Breast CarcinomaStage IIIC Breast Cancer AJCC v7Stage IV Breast Cancer AJCC v6 and v7
Interventions
DRUG

Endoxifen Hydrochloride

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (3)

55905

Mayo Clinic in Rochester, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

32224-9980

Mayo Clinic in Florida, Jacksonville

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH